Mr. DeLucia has over 20 years of experience in the biopharmaceutical industry including early stage drug development, business development and management of strategic partnerships. Mr. DeLucia has been CEO ImmuRx, an immunotherapy based company co-founded with Dr. Noelle, and CEO of MIST Inc., a breast cancer imaging company. Prior to MIST, he led the development of a drug development technology platform at Millennium Pharmaceuticals which was spun out as part of a separate company in 2003. He has an M.S. from MIT and a B.A. from Dartmouth College.
Dr. Noelle is CSO and co-founder of ImmuNext and Professor of Immunology at the Geisel School of Medicine at Dartmouth. His laboratory discovered the natural CD40 ligand, CD154, and the checkpoint regulator, VISTA. Dr. Noelle is in the top 5% of NIH funded scientists for total funding over his career and is a Fellow in the Academy of Medical Sciences.
Dr. Rothstein is a translational immunobiologist with experience in lead discovery, PK/PD, toxicological assessment and POC models for immune modulatory drugs. Prior to ImmuNext he was Director of Inflammation Research at Amgen where he championed a novel class of immunomodulatory drugs for the treatment of autoimmune disease. He was involved in evaluating and developing Amgen's early immune-oncology drug pipeline including novel bispecifics such as BiTEs and checkpoint inhibitors. In addition, he developed novel drugs to target immunometabolism. Dr. Rothstein received his Ph.D. in Tumor Immunology from the University of Chicago and was Professor of Otolaryngology-HNS at the Kimmel Cancer Institute of Thomas Jefferson University for 13 years. Prior to his industrial research his laboratory was responsible for discovering an association between oncogenes and chronic inflammation leading to a better understanding of the tumor microenvironment.